Hyperthermia for Metastatic Pancreatic Cancer with Liver Metastases

An Honest Look at What We Know

Yoon Hang “John” Kim, MD, MPH, FAAMA   |   directintegrativecare.com

Few conversations in my integrative oncology work are harder than the one that begins, “I have metastatic pancreatic cancer, and it’s already in my liver. What else can I do?” Patients arrive having already heard the brutal statistics. They’ve usually started—or are weighing—a gemcitabine/nab-paclitaxel or FOLFIRINOX regimen. And almost always, somewhere in their search, they’ve come across the word hyperthermia. They want to know whether it’s real medicine, snake oil, or something in between.

My honest answer is: it’s something in between, and the in-between deserves a careful, non-evangelical look. Hyperthermia is a legitimate area of investigation with biologically plausible mechanisms and a small but suggestive clinical signal in advanced pancreatic cancer. It is also not standard of care, the evidence base is mostly retrospective, and it is not a substitute for systemic therapy. Both halves of that sentence matter.

What “hyperthermia” actually means in oncology

In an oncology context, hyperthermia means deliberately heating tumor tissue to roughly 39 to 43.5°C—well above normal body temperature, but below the temperatures used in ablation. The heat is delivered locally or regionally using radiofrequency, microwave, or ultrasound energy, most commonly as an adjunct to chemotherapy or radiotherapy.¹

The mechanistic rationale is reasonable and increasingly well characterized:

• Improved perfusion and drug delivery to poorly vascularized tumors like pancreatic adenocarcinoma
• Increased tumor oxygenation, which can sensitize cells to radiation
• Inhibition of DNA repair after chemo- or radio-induced damage
• Direct apoptotic and immunogenic cell death at higher temperatures, potentially priming an anti-tumor immune response¹⁻²

In other words, hyperthermia is not framed as a stand-alone cure. It is framed as a sensitizer—something that may make conventional therapy work harder. That framing matters when patients come in asking whether they can replace chemotherapy with heat. The answer is no.

What the data actually show in advanced pancreatic cancer

The most-cited clinical evidence in this space comes from a series of Italian retrospective observational studies of modulated electro-hyperthermia (mEHT)—a 13.56 MHz capacitive radiofrequency technique that targets malignant cell membranes and the tumor extracellular matrix.

In the largest of these, Fiorentini and colleagues retrospectively analyzed 217 patients with stage III–IV pancreatic cancer across nine Italian centers. Patients receiving chemotherapy plus mEHT had a median overall survival of about 20 months versus 9 months for chemotherapy alone, with partial response rates of 45% vs 24% and progression rates of 4% vs 31%, respectively.² An earlier 158-patient analysis from the same group reported similar magnitudes—roughly 19.5 vs 11 months median overall survival, and 12 vs 3 months progression-free survival, favoring the mEHT arm.³ A separate 106-patient palliative cohort reported a median overall survival of 18 months in the mEHT group versus about 11 months in controls.⁴

These are not small differences. They are also not randomized data. What they are is a consistent signal across overlapping retrospective cohorts using similar protocols (60–150 W, 40–90 minutes, three sessions per week, alongside gemcitabine-based regimens)—enough to take seriously, not enough to call practice-changing.

A broader systematic review of 14 hyperthermia trials in pancreatic cancer found median overall survival ranging from roughly 6 to 18.6 months with hyperthermia plus chemotherapy and/or radiotherapy, generally exceeding historical controls, with overall response rates around 30%.⁵ Encouraging, but heterogeneous and prone to selection bias.

What about the liver metastases specifically?

This is where my patients always push, because liver mets are usually what is driving their fear and their numbers. Here the data are thinner.

The Italian cohorts included patients with metastatic disease, and liver was the most common metastatic site, but outcomes are reported for the whole stage III–IV population, not stratified by hepatic involvement.²⁻³ A small Japanese stage IV series of 28 patients receiving hyperthermia plus chemotherapy described radiologic shrinkage of both pancreatic primaries and liver metastases in some cases, with falling tumor markers, including a detailed case of a pancreatic tail tumor with multiple liver metastases that contracted after roughly five months of combined hyperthermia and gemcitabine/nab-paclitaxel. The authors are appropriately modest in their conclusions: hyperthermia “has a possibility” to help in stage IV disease, but the numbers are tiny and uncontrolled.

Liver-directed thermal approaches like microwave or radiofrequency ablation are a different animal—those are focal ablative treatments for selected lesions, not regional sensitizers. They have a defined role in oligometastatic disease and should not be confused with the regional/systemic hyperthermia I am describing here.

The varieties of hyperthermia under study

• Modulated electro-hyperthermia (mEHT)—13.56 MHz capacitive radiofrequency, applied regionally over the pancreas concurrently with chemotherapy. This is the approach with the most published clinical data in pancreatic cancer.²⁻⁴
• Deep regional hyperthermia—radiofrequency or ultrasound systems delivering “fever-range” heat to deep tumors. Devices are being tested in academic trials in combination with chemotherapy, radiotherapy, and immunotherapy for pancreatic ductal adenocarcinoma.
• Magnetic nanoparticle hyperthermia—injected iron-oxide nanoparticles activated by an alternating magnetic field, allowing more selective tumor heating. This is largely preclinical and very early translational work, and is not standard care.

Safety, access, and cost

The reassuring part of the published experience is that hyperthermia, when delivered competently, generally adds modest toxicity—local discomfort, skin erythema, fatigue—and serious adverse events are uncommon in the published series.²⁻⁴ This matters for patients already shouldering the toxicity of FOLFIRINOX or gemcitabine/nab-paclitaxel; the question is rarely whether hyperthermia will be intolerable, but whether it will actually move the disease.

The harder realities are practical:

• The National Cancer Institute classifies hyperthermia as investigational in oncology; it is offered mainly at specialized centers and within trials.¹
• Major guidelines (NCCN, ASCO, ESMO) for metastatic pancreatic cancer continue to prioritize systemic regimens—FOLFIRINOX or gemcitabine/nab-paclitaxel—and selected local therapies. Hyperthermia is positioned as adjunctive or research, not standard.⁶
• Insurance coverage in the United States is poor. Many patients pay out of pocket, often thousands of dollars per cycle, sometimes traveling internationally to receive treatment. That financial toxicity is a real and underappreciated harm.

How I actually counsel patients

When a patient with metastatic pancreatic cancer and liver involvement asks me about hyperthermia, I try to do four things.

First, I anchor on systemic therapy. Whatever else we add, the foundation is an evidence-based chemotherapy regimen tailored to performance status—typically FOLFIRINOX in fit patients, gemcitabine/nab-paclitaxel otherwise—at a center experienced in pancreatic oncology. Hyperthermia, if pursued, is meant to augment this, not replace it.

Second, I am transparent about evidence quality. The mEHT data are interesting and consistent, but they are retrospective and selection-biased. I tell people: this could be a real effect, or it could be partly the kind of patient who pursues it. Both are possible. Honest medicine sits with that uncertainty rather than papering over it.

Third, I help them think about the trade-offs concretely. Time, money, travel, energy reserves, family logistics, and the opportunity cost of not doing other things—rest, time at home, hospice planning when appropriate—all belong in the decision. Roughly one in three patients does not respond meaningfully to any given oncologic therapy, and hyperthermia is no exception.

Fourth, when patients do choose to pursue it, I help them do it well: at an experienced center, ideally within a clinical trial, alongside their oncology team rather than instead of it, with clear stop criteria (we will reassess at three months with imaging and tumor markers), and with attention to the rest of the integrative picture—nutrition, sleep, stress physiology, the gut–brain axis, glycemic control, and meaningful psychological and spiritual support.

The bottom line

Hyperthermia for metastatic pancreatic cancer with liver metastases is a plausible adjunct with a real but limited evidence base. The biology makes sense. The retrospective signal—particularly from the Italian mEHT cohorts—is consistent enough that I do not dismiss it. But the evidence is not yet at the level of randomized, controlled, practice-changing data, and any patient considering it deserves an honest conversation about cost, access, and how it fits alongside, not instead of, standard systemic therapy.

If you are walking this road yourself or with a loved one, my recommendation is simple: anchor on a strong oncology team, ask explicitly about clinical trials that include hyperthermia or other novel sensitizers, and bring an integrative physician into the conversation early—not at the end—so the whole picture of body, mind, microbiome, and meaning is being tended to from day one. That is what honest medicine looks like in a disease this hard.

References

1. National Cancer Institute. Hyperthermia to Treat Cancer. https://www.cancer.gov/about-cancer/treatment/types/hyperthermia

2. Fiorentini G, Sarti D, Mambrini A, et al. Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023;14(6):215–226. doi:10.5306/wjco.v14.i6.215. PMID: 37398545.

3. Fiorentini G, Sarti D, Ranieri G, et al. Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients. World J Clin Oncol. 2021;12(11):1064–1071. doi:10.5306/wjco.v12.i11.1064. PMID: 34909400.

4. Fiorentini G, Sarti D, Casadei V, et al. Modulated electro-hyperthermia as palliative treatment for pancreatic cancer: A retrospective observational study on 106 patients. Integr Cancer Ther. 2019;18:1534735419878505. doi:10.1177/1534735419878505. PMID: 31561722.

5. van der Horst A, Versteijne E, Besselink MGH, et al. The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. Int J Hyperthermia. 2018;34(7):969–979. doi:10.1080/02656736.2017.1401126.

6. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. NCCN.org (current version).

Disclosure and disclaimer: This article is for educational purposes and does not constitute individual medical advice. Decisions about cancer treatment should be made in partnership with a qualified oncology team. Dr. Kim has no financial relationships with any hyperthermia device manufacturer.